Golcadomide clinical trials
Also written BMS-986369 and CC-99282.
How each study uses golcadomide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the golcadomide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2024 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 12
Celgene (7) · Bristol-Myers Squibb (4) · M.D. Anderson Cancer Center (2) · The Lymphoma Academic Research Organisation (2) · Olivia Newton-John Cancer Research Institute (1) · Allison Winter (1) · Seoul National University Hospital (1) · City of Hope Medical Center (1)
Often tested with
Tested in the same studies.
Rituximab (1) · Iberdomide (1) · Vincristine (1) · Polatuzumab vedotin (1) · Polatuzumab (1) · Glofitamab (1) · Poseltinib (1) · Roginolisib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test golcadomide, phase 3 first.
- Aug 2027Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaPhase 3 · Celgene
- Dec 2026A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionPhase 1 · Bristol-Myers Squibb
- Dec 2026CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaPhase 1 · Nathan Denlinger
- Mar 2027Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of RelapsePhase 2 · The Lymphoma Academic Research Organisation
- Apr 2027A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Phase 1/2 · Celgene
- Jun 2027Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyPhase 2 · Mayo Clinic
- Jun 2027Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses golcadomide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingPhase 1/2The Lymphoma Academic Research OrganisationNCT07018752Written as golcadomide
- Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07917832Written as golcadomide
- Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06108232Written as CC-99282
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT07578077Written as Golcadomide
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingPhase 2Mayo ClinicNCT06834373Written as Golcadomide
- A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionRecruitingPhase 1Bristol-Myers SquibbNCT07763418Written as Golcadomide
- A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)RecruitingPhase 2Fondazione Italiana Linfomi - ETSNCT06835530Written as Rituximab + Golcadomide (CC-99282)
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasNot yet recruitingPhase 1Allison WinterNCT07608731Written as Golcadomide
- Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of RelapseRecruitingPhase 2The Lymphoma Academic Research OrganisationNCT06271057Written as golcadomide
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as Golcadomide
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaRecruitingPhase 1Nathan DenlingerNCT06209619Written as Golcadomide
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Seoul National University HospitalNCT07269639Written as Golcadomide + Poseltinib + Rituximab
- Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.Active, not recruitingPhase 2Olivia Newton-John Cancer Research InstituteNCT05788081Written as golcadomide
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingPhase 1/2Bristol-Myers SquibbNCT06035497Written as BMS-986369
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruitingPhase 2CelgeneNCT06425302Written as Golcadomide
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingPhase 1CelgeneNCT04884035Written as CC-99282
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaActive, not recruitingPhase 3CelgeneNCT06356129Written as Golcadomide
- Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell TherapyWithdrawnPhase 1/2University of PittsburghNCT06767956Written as GOLCADOMIDE
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingPhase 1/2CelgeneNCT03930953Written as CC-99282
- Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedPhase 1CelgeneNCT06535399Written as BMS-986369
See all 23 studies that test golcadomide →
Given beside what is tested · 5 — golcadomide is usual care or a partner of the new treatment
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruitingPhase 1/2Bristol-Myers SquibbNCT06090539Written as Golcadomide
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1Hoffmann-La RocheNCT05169515Written as Golcadomide
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingPhase 2GenmabNCT05283720Written as CC-99282
- A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy ParticipantsCompletedPhase 1CelgeneNCT06363630Written as Golcadomide
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/2CelgeneNCT03310619Written as CC-99282
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered1
Codes
What other systems call golcadomide · ClinicalTrials.gg INT014445
- UNII (FDA) 29HLR8Z5BRGOLCADOMIDEOne source FDA
- NCI Thesaurus C172396GolcadomideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 29HLR8Z5BR | GOLCADOMIDE | One source FDA |
| NCI Thesaurus | C172396 | Golcadomide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.